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Abstract
Background: Treatment with prostaglandin inhibitors can reduce renal function and impair renal water and
sodium excretion. We tested the hypotheses that a reduction in prostaglandin synthesis by ibuprofen treatment
during fasting decreased renal water and sodium excretion by increased absorption of water and sodium via the
aquaporin2 water channels and the epithelial sodium channels.
Methods: The effect of ibuprofen, 600 mg thrice daily, was measured during fasting in a randomized, placebo-
controlled, double-blinded crossover study of 17 healthy humans. The subjects received a standardized diet on day
1, fasted at day 2, and received an IV infusion of 3% NaCl on day 3. The effect variables were urinary excretions of
aquaporin2 (u-AQP2), the beta-fraction of the epithelial sodium channel (u-ENaCbeta), cyclic-AMP (u-cAMP),
prostaglandin E2 (u-PGE2). Free water clearance (CH2O), fractional excretion of sodium (FENa), and plasma
concentrations of vasopressin, angiotensin II, aldosterone, atrial-, and brain natriuretic peptide.
Results: Ibuprofen decreased u-AQP2, u-PGE2, and FENa at all parts of the study. During the same time, ibuprofen
significantly increased u-ENaCbeta. Ibuprofen did not change the response in p-AVP, u-c-AMP, urinary output, and
free water clearance during any of these periods. Atrial-and brain natriuretic peptide were higher.
Conclusion: During inhibition of prostaglandin synthesis, urinary sodium excretion decreased in parallel with an
increase in sodium absorption and increase in u-ENaCbeta. U-AQP2 decreased indicating that water transport via
AQP2 fell. The vasopressin-c-AMP-axis did not mediate this effect, but it may be a consequence of the changes in
the natriuretic peptide system and/or the angiotensin-aldosterone system
Trial Registration: Clinical Trials Identifier: NCT00281762.
Background
Inhibition of prostaglandin synthesis reduces renal water
and sodium excretion in the kidneys, especially in
patients with renal disease or heart failure. A recent
study suggested that increased absorption of sodium
took place in the thick ascending limb of Henle during
prostaglandin inhibition [1]. However, the distal part of
the nephron might also participate in this process, i. e.
by an increase in the absorption of water and sodium
via the aquaporine2 water channels (AQP2) and epithe-
lial sodium channels (ENaC), respectively. The effect of
prostaglandin inhibition on renal water and sodium
excretion is most pronounced during conditions with an
increased prostaglandin synthesis. During fasting, urin-
ary concentrating and diluting ability was reduced, and
AQP2 expression down regulated, possibly due to an
antagonizing effect of increased prostaglandin level on
the effect of vasopressin on water transport in the prin-
cipal cells [2-5]. In addition, fasting induced natriuresis
in man, and prostaglandin E2 inhibited sodium
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[6-8]. Thus, elevated renal levels of prostaglandin during
fasting might mediate natriuresis via ENaC [9]. The
degree of water transport via AQP2 is reflected by the
level of urinary excretion of aquaporine2 (u-AQP2) [10].
Correspondingly, the sodium transport via ENaC is sup-
posed to be reflected by level of urinary excretion of the
b-fraction of ENaC (u-ENaCb). This is the first report
with measurement of u-ENaCb as a biomarker of the
activity of the epithelial sodium channels in the distal
tubuli.
In the present study, we measured the effect of inhibi-
tion of prostaglandins on u-AQP2 and u-ENaCb during
fasting. We wanted to test the hypotheses that a reduc-
tion of prostaglandin synthesis by ibuprofen treatment
during fasting would 1. Increase u-AQP2 and u-ENaCb
during baseline condition and change the renal response
to hypertonic saline infusion, and 2. The increased renal
water and sodium absorption during ibuprofen treat-
ment was mediated via increased transport via AQP2
and ENaC.
We performed a randomized, placebo controlled
crossover study in healthy humans during baseline con-
dition and during hypertonic saline infusion to examine
the effect of ibuprofen on renal handling of water and
sodium during fasting. We measured the effect of ibu-
profen/placebo on u-AQP2, u-ENaCb, fractional urinary
excretion of sodium (FENa), urinary excretion of prosta-
glandin E2 (u-PGE2), urinary excretion of cyclic AMP
(u-c-AMP), free water clearance (CH2O ), and plasma
concentrations of renin (PRC), angiotensin II (p-Ang II),
aldosterone (p-Aldo), vasopressin (p-AVP), atrial
natriuretic peptide (p-ANP), and brain natriuretic pep-
tide (p-BNP).
Methods
Participants
Inclusion criteria: Both males and females; age 18-65 years;
body mass index <30. Exclusion criteria: Clinical signs or
history of disease in the heart, lungs, kidneys or endocrine
organs; abnormal laboratory tests (blood hemoglobin,
white cell count, platelet counts, plasma concentrations of
sodium, potassium, creatinine, albumine, bilirubine, ala-
nine-aminotransferase, and cholesterol; blood glucose and
albumin and glucose in urine); malignancies; arterial
hypertension (i.e. casual blood pressure >140/90 mmHg);
alcohol abuse (more than 21 drinks per week for males
and more than 14 for females); medical treatment; preg-
nancy; breast-feeding; lack of oral contraceptive treatment
to women in the fertile age; intercurrent diseases; pro-
blems with blood sampling or urine collection; allergy to
ibuprofen; medicine abuse; donation of blood less than 1
month before the study; and unwillingness to participate.
Withdrawal criteria: Development of one or more of the
exclusion criteria.
Ethics
The Scientific Committee of Ringkøbing, Ribe and
Southern Jutland Counties (j.no.2623-04) approved the
study. All participants received written information and
gave their consent by signature. The study was carried
out in compliance with the Helsinki Declaration.
Design
The study was randomized, placebo-controlled, double
blind, and over-crossed. There was a time interval of 2
weeks between the two examinations. Each examination
took three days.
Recruitment
Participants were recruited by advertisements in public
and private institutions.
Diet and fluid intake
The normal energy requirement was calculated with the
formula: weight (kg) * 100 (kJ) * activity factor (AF). AF
ranged from 1.3 to 2.4 with a possible extra of 0.3 for
physical activity in the spare time, e.g. 30 min. of sport
5-6 times a week. AF of 1.3 indicates no physical activ-
ity. AF of 1.4-1.5 indicates sedentary work without phy-
sical activity in the spare time. AF of 1.6-1.7 indicates
work with walking during work hour and/or physical
activity in the spare time, AF of 1.8-1.9 corresponds to
shop assistant, (standing/walk all day), AF 2.0-2.4 indi-
cates hard physical activity with or without physical
activity in the spare time. The food had a specified
energy amount with carbonhydrates (55% of the total
energy), protein (15% of the total energy), and fat (30%
of the total energy). The diet contained three main
meals and three small meals. The participants were not
allowed to add any spices or sodium to the meals or to
divide the meals into bigger or smaller portions. The
participants drank tap water 35 mL/kg each 24-hour
and nothing else. They maintained normal physical
activity during the study.
Procedure
Subjects were studied on three consecutive days. Table 1
shows the experimental design.
Day 1 (24 hours): The participants ate the specified
diet, drank tap water 35 mL/kg body weight, and main-
tained normal physical activity.
Day 2 (24 hours): The participants fasted, drank tap
water 35 mL/kg body weight maintained normal physi-
cal activity, and collected urine during 24 hours. They
received a tablet of 600 mg ibuprofen or placebo at
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at 07.00 a.m.
Day 3: The participants arrived at 7:30 a.m. in the
laboratory. An intravenous catheter was placed in fossa
cubiti on each side; one for collection blood samples,
the other for infusion of the
51 Cr-EDTA and hyper-
tonic saline. Urine was collected from 7:30-9:30 to
measure the effect variables after a period of 24 hours
of fasting. Afterwards, urine was collected in the fol-
lowing seven periods: 09:30-10:00 a.m. (P-1), 10:00-
10:30 a.m. (P-2), 10:30-11:00 a.m. (P-3), 11:00-11:30 a.
m. (P-4), 11:30-12:00 a.m. (P-5), 12:00-12:30 p.m. (P-6)
and 12:30-01:00 p.m. (P-7). Urine was analyzed for u-
AQP-2, u-ENaC, u-Osm, u-Na, u-K, u-creat, u-cAMP,
u-PGE2,u -
51Cr-EDTA. The subjects voided in the
standing or sitting position. Otherwise, they were in
the supine position during the examination. Blood
samples were taken every 30 min. starting at 09.30 a.
m. for analysis of p-AVP, p-Osm, p-K, p-Na, p-Crea,
p-albumin, p-
51Cr-EDTA. In addition, blood samples
for measurements of p-Ang II, p-ANP, p-BNP, p-PRC,
and p-ALDO were drawn at 08.00 a.m., 11.00 a.m.,
12.00 p.m., and 01.00 p.m. A total amount of 350 mL
blood was drawn during the each study day. The blood
drawn at blood sampling was immediately substituted
with isotonic saline. From 11.00 a.m. to 11.30 a.m.
(P-4), 3% saline was infused, 7 ml/kg body weight.
Blood pressure and pulse rate were measured every
30 min. during the examination.
The participants were weighed before (day 3 at 07:30
a.m.) and after the trial (01:30 p.m.).
Effect variables
Main effect variables were u-AQP2 and u-ENaC. The
other effect variables were u-PGE2,u - C AMP,p - A V P ,
CH2O urine volume, FENa,p - O s m ,u - O s m ,p - P R C ,
p-Aldo, p-ANP, p-BNP and p-Ang II.
Number of participants
An increase in u-AQP2 of 0.2 ng/min was considered
the relevant difference between ibuprofen and placebo.
The standard deviation was estimated to be 0.15 ng/
min. With a level of significance of 5% and a power of
90%, 14-15 healthy subjects needed to be included in
the trial.
Test substance
The Hospital Pharmacy conducted the randomization
and prepared the medication. The tablets were kept in a
sealed container with tablets for one day. Each tablet
contained either ibuprofen 600 mg or placebo.
Measurements
Glomerular filtration rate was measured using the con-
stant infusion clearance technique with
51Cr-EDTA as a
reference substance.
U-AQP-2 was measured by radioimmunoassay as pre-
viously described, and antibodies were raised in rabbits
to a synthetic peptide corresponding to the 15 COOH-
terminal amino acids in human AQP2 to which was
added an NH2-terminal cystein for conjugation and affi-
nity purification [10]. Minimal detection level was
32 pg/tube. The coefficients of variation were 11.7%
(inter-assay) and 5.9% (intra-assay).
U-c-AMP was measured using a kit obtained from
R&DS y s t e m s ,M i n n e a p o l i s ,M N ,U S A .M i n i m a l
detection level was 12.5 pmol/tube. The coefficients of
variation were 6.9% (inter-assay) and 5.3% (intra-assay).
ENaCb was measured by a newly developed RIA. Urine
samples were kept frozen at -20°C until assayed. ENaCb
was synthesized and purchased by Lofstrand Labs
Limited - Gaithersburg, Maryland, USA, see Appendix.
U-PGE2 was measured by a kit from Assay Designs, Inc.,
Ann Arbor, MI, USA. The coefficients of variations were
10.9% (inter-assay) and 6.3% (intra-assay).
Table 1 Overview of the study design
Day 1 Day 2 Examination day
Time 7:00
AM
3:00
PM
11:00
PM
7:00
AM
3:00
PM
11:00
PM
7:00
AM
8:00
AM
9:00
AM
9:30
AM
10:00
AM
10:30
AM
11:00
AM
11:30
AM
12:00
AM
12:30
AM
13:00
AM
Food specified diet Fasting Fasting
Water 35 ml/kg body
weight
35 ml/kg body
weight
175 ml every ½ hour
Ibuprofen/
placebo
xxx x
Urine
samples
24 hour urine
collection
2 ½ hour urine collection Baseline urine
collection
1234
Blood
samples
↑ ↑ ↑ ↑↑↑↑↑↑↑
3% saline
infusion
7 ml/kg body
weight
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3000 rpm at 4°C. Plasma was separated from blood cells
and kept frozen at -20°C until assayed. AVP, ANP, BNP,
and Ang II were extracted from plasma with C18 Sep-
Pak (Water associates, Milford, MA, USA), and subse-
quently determined by radioimmunoassays [11,12]. The
antibody against AVP was a gift from Professor Jacques
Dürr, Miami, FL., USA. Minimal detection level was 0.5
pmol/L. The coefficients of variation were 13% (inter-
assay) and 9% (intra-assay). Rabbit anti-ANP antibody
was obtained from Department of Clinical Chemistry,
Bispebjerg Hospital, Denmark. Minimal detection level
was 0.5 pmol/L, coefficients of variation were 12%
(inter-assay) and 10% (intra-assay). Rabbit anti-BNP
antibody without cross-reactivity with urodilatin and
a-ANP was used. Minimal detection level was 0.5 pmol/
L plasma. The coefficients of variation were 11% (inter-
assay) and 6% (intra-assay). The antibody against Ang II
was obtained from Department of Clinical Physiology,
Glostrup Hospital, Denmark. Minimal detection level
was 2 pmol/L. The coefficients of variation were 12%
(inter-assay) and 8% (intra-assay).
Aldosterone in plasma was determined by radioimmu-
noassay using a kit from Diagnostic Systems Labora-
tories Inc., Webster, Texas, USA. Minimal detection
level was 22 pmol/L. The coefficients of variations were
8.2% (inter-assay) and 3.9% (intra-assay).
PRC is determined by radioimmunoassay using a kit
from CIS Bio International, Gif-Sur-Yvette Cedex,
France. Minimal detection level was 1 pg/ml. The coeffi-
cients of variations were 14.5% (inter-assay) and 4.5%
(intra-assay).
Plasma and urinary osmolality were measured by
freezing-point depression (Advanced Model 3900 multi-
sampling osmometer).
Blood pressure was measured with UA-743 digital
blood pressure meter (A&D Company, Tokyo, Japan)
Plasma and urinary concentrations of sodium and
potassium were measured by routine methods at the
Department of Clinical Biochemistry, Holstebro Hospi-
tal, Denmark.
All clearances were standardized to a body surface
area of 1.73 m
2.
Statistics
Statistical level of significance was P < 0.05 in all ana-
lyses. We used A General Linear Model with Repeated
Measures for comparison between ibuprofen treatment
and placebo during fasting when several measurements
were done during the examination. A paired t-test was
used for comparison between two groups. Bonferroni
correction was used when appropriate. Values are given
as mean ± SD.
Results
Demographics
Twenty subjects were allocated to the study. Three par-
ticipants were excluded. The first was not able to fast
for 24 hours, the second needed acute medication due
to an intercurrent disease, and in the third blood sam-
pling could not be performed. Seventeen participants
were included in the study, 7 women and 10 men with
a mean age of 33 ± 8 years. Blood pressure was 124/72
± 14/9 mmHg. Blood samples showed: B-Hemoglobin
8.8 ± 0.79 mmol/L, P-Sodium 139 ± 2.4 mmol/L,
P-Potassium 3.8 ± 0.3 mmol/l, P-Albumin 42 ± 1.5 g/L,
P-Creatininium 78 ± 15 μmol/L, P-Bilirubin 8 ±
3 μmol/L, P-Alanintransaminase 23 ± 9 U/L, P-Glucose
5.2 ± 0.8 mmol/L, P-Cholesterol 4.4 ± 0.7 mmol/L.
Effect of ibuprofen during fasting on u-AQP2, u-ENaCb,u -
PGE2, u-c-AMP, CH2O, and p-AVP
Table 2 shows the effect of fasting during a 24 hours
period and during 2½ hours immediately after 24 hours
fasting. During fasting ibuprofen reduced u-PGE2 by
50% (P < 0.03), u-AQP2 by 17% (P < 0.01), and
u-AQP2/u-Crea by 18% (P < 0.01). U-ENaCb was
increased by 170% (P < 0.0001). We found no statisti-
cally significant changes in urine volume, CH2Oa n d
u-c-AMP despite a tendency to lower values during ibu-
profen treatment.
After fasting ibuprofen reduced u-PGE2 by 44% (P <
0 . 0 2 ) ,u - A Q P 2 / u - C r e ab y2 7 %( P<0 . 0 3 ) ,a n du - E N a C b
was increased by 210% (P < 0.0001) in 2½ hours urine
collection immediately after the 24 hours fasting period.
We measured no statistically significant changes in
urine output, CH2O and u-c-AMP despite a tendency to
lower values during ibuprofen treatment.
Effect of ibuprofen on the response to hypertonic saline
infusion
Table 3 shows the effect variables before, during and
after hypertonic saline infusion. U-AQP2, p-AVP, u-
Osm and p-Osm increased significantly during infusion
of 3% saline. After 120 min. U-AQP2 increased by 29%
(p < 0.01) during ibuprofen treatment and by 51% (p <
0.001) during placebo. The level of u-AQP2 was signifi-
cantly lower during ibuprofen treatment at three of four
measurements after 3% saline infusion. During ibupro-
fen treatment we found that ENaCb was increased sig-
nificantly and approximately 3 fold at all times during
the hypertonic saline infusion (figure 1). After 60 min
we found a modest, but significant reduction in ENaCb
by 12% (p < 0.001), and this reduction remained
unchanged during the study. During placebo ENaCb
levels were reduced significantly at 30 min and again
120 after hypertonic saline infusion. P-AVP increased by
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the ibuprofen group and by 118% (P < 0.001) in the pla-
cebo group. U-Osm increased by164% (p < 0.001)
immediately after 3% saline infusion in the ibuprofen
group and by 157% (P < 0.001) in the placebo group.
S-Osm increased 3% (p < 0.001) immediately after 3%
saline infusion in the ibuprofen group and by 2.5% (P <
0.001) in the placebo group. The levels of P-AVP,
u-Osm and s-Osm did not differ between ibuprofen and
placebo. Urine volume and CH2O decreased by 55% (p <
0.001) and 105% (p < 0.001), respectively, during ibupro-
fen administration and by 57% (p < 0.001) and 109%
(p < 0.001) during placebo. Urine volume and CH2O did
not differ significantly between the two groups. U-PGE2
did not change significantly during 3% saline infusion.
The initial reduction in u-PGE2 persisted during ibupro-
fen treatment both during and after 3% saline infusion.
GFR and u-c-AMP did not change significantly during
3% saline infusion and did not differ between ibuprofen
and placebo treatment.
Effect of ibuprofen on FENa and total sodium excretion
During 24 hours of fasting the total sodium excretion
was reduced by 37% (p < 0.001) during Ibuprofen treat-
ment, and FENa was reduced by 35% (p < 0.001). figure 2
shows that ibuprofen reduced FENa significantly at base-
line, during and after hypertonic saline infusion. The
changes after 3% saline infusion were the same in the
t w og r o u p s ,b u ta td i f f e r e n tl e v e l s .F E Na at baseline was
36% (p = 0.006) higher during placebo treatment com-
pared with ibuprofen, and this difference remaind after
infusion of hypertonic saline. Urinary sodium excretion
increased significantly from baseline (Placebo: 1129 ±
509 μmol/min; Ibuprofen 827 ± 541 μmol/min) to the
level during infusion (Placebo: 2856 ± 1068 μmol/min;
Ibuprofen 3305 ± 941 μmol/min) and in the period after
infusion (Placebo: 5603 ± 1907 μmol/min; Ibuprofen
5978 ± 1793 μmol/min).
Effect of ibuprofen on vasoactive hormones after 24
hours fasting and after hypertonic saline infusion
Ibuprofen treatment increased p-BNP significantly dur-
ing all periods of the study, except for 60 min after infu-
sion (Table 4). P-BNP increased by 61% (p < 0.03)
immediately after 24 hours of fasting by ibuprofen. At
baseline (before saline infusion) p-BNP was increased by
60% (p < 0.01). No significant increase in p-BNP values
there observed 6o min after hypertonic saline infusion,
but a clearer tendency was seen to a higher levels during
ibuprofen (p < 0.08). The increase in p-BNP was 42%
120 min after hypertonic saline infusion (p < 0.02).
P-ANP tended to increase using A General Linear
Model With Repeated Measurements (p < 0.055). At
baseline, P-ANP increased by 29% (p < 0.03), and
60 min after hypertonic saline infusion the increase was
20% (p < 0.03). No significant difference was observed
120 min after hypertonic saline infusion. Both p-Ang II
and p-aldo tended to fall during ibuprofen treatment.
Effect of ibuprofen on blood pressure
At baseline blood pressure was 115/64 ± 9/8 mmHg and
pulse rate was 57 ± 8 beats/min during Ibuprofen treat-
ment. The corresponding values during placebo did not
deviate significantly, blood pressure was114/65 ± 11/7
mmHg and pulse rate 56 ± 7 beats/min.
The response to 3% saline infusion was measured 30
min after infusion. Systolic blood pressure was unchanged
during ibuprofen treatment and increased by 4 mmHg
Table 2 Effect of ibuprofen on urine volume, urinary excretion of prostaglandin E2 (U-PGE2), aquaporin 2 (U-AQP2),
urinary epithelial sodium channel (U-ENaCb ), cyclic AMP (U-C-AMP), free water clearance (C H2O), serum osmolality (s-
Osm) and plasma arginine vasopressin (P-AVP) during 24 hours fasting and 2½ hours period immediately after 24
hours fasting in a randomized placebo-controlled, cross over study in 17 healthy subjects
24 hours fasting urine collection 2½ hours urine collection immediately after 24 hours fasting
Ibuprofen Placebo P Ibuprofen Placebo P
Urine volume (ml) 2533 (718) 2784 (770) NS 2.75 (1.39) 3.30 (1.56) NS
U-PGE2 (pg/min) 270.91 (95.4) 540.97 (365.1) 0.027 282 (111) 504 (307) 0.02
U-AQP-2 (ng/min) 1.21 (0.30) 1.48 (0.27) 0.00016 3.42 (2.07) 4.92 (3.09) NS
U-AQP-2/U-Crea (ng/μmol) 128.9 (21.5) 158.0 (30.2) 0.00002 0.29 (0.17) 0.40 (0.18) 0.024
U-ENaCb/U-Crea (pg/μmol) 38.7 (13) 14.3 (3) 0.0000002 40.1 (11) 12.9 (4) 0.000000002
U-c-AMP (pmol/min) 5737 (2080) 6381 (3041) NS 10909 (7061) 13762 (9571) NS
CH2O (ml/min) 0.029 (0.47) -0.047 (0.36) NS 1.30 (1.40) 1.85 (1.29) NS
Total Na
+ excretion (mmol/24 hour) 95 (44) 152 (33) 0.00001 x x x
FENa 0.46(0.16) 0.71 (0.20) 0.000006
S-Osm (mosm/kg H2O) x x x 283 (2.6) 284 (4.1) NS
P-AVP (pmol/l) x x x 0.86 (0.21) 0.78 (0.20) NS
Values are means and (SD). A paired t-test was used for comparison of means.
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min (p < 0.01) during ibuprofen treatment and 9 beats/
min (p < 0.01) during placebo. Diastolic blood pressure
decreased by 2 mmHg (p < 0.05) during ibuprofen treat-
ment and were unchanged during placebo.
The response to 3% saline infusion was measured 60
min after infusion. Systolic blood pressure was
unchanged during both ibuprofen and placebo treat-
ment. Pulse rate was significantly increased in both
groups by 7 Beats/min (p < 0.01) during ibuprofen and
6 beat/min (p < 0.01) during placebo. Diastolic blood
pressure was decreased in both groups (p < 0.05). There
were no statistical differences in blood pressure and
pulse rate between ibuprofen and placebo at baseline,
during and after 3% saline infusion.
Effect of ibuprofen and fasting on body weight and
p-albumin
Body weight were 77.6 kg in the placebo group and 78.1
kg in the ibuprofen group (P < 0.07) after the study day,
Table 3 Urinary aquaporin-2 creatinine adjusted (U-AQP2/u-crea), urinary epithelial Na
+ channel (U-ENaCb/u-crea),
plasma arginine vasopressin (AVP), urine osmolality (U-OSM), serum osmolality (S-OSM), urinary excretion of
prostaglandin2 (U-PGE2), free water clearance (CH2O), urinary excretion of cAMP (U-CAMP), and Glomerular filtration
rate (GFR)
Baseline 30 min 60 min 90 min 120 P
U-AQP2/u-crea (ng/μmol)
Placebo 154(33) 189(69) ** 200(61) *** 225(75) *** 233(76) *** 0.005
Ibuprofen 161 (25) 161(62) 202(68)* 199(52)** 208(64)**
P-value NS 0.036 NS 0.008 0.014
U-EnaC/u-crea (pg/μmol) Placebo 11.6(3) 13.4(3) ** 12.8(4) 13.4(4) 13.7(4) ** <0.0001
Ibuprofen 44.8(13) 44.1 (10) 38.6 (10) ** 39.1 (10) ** 35.8 (9) ***
P-Value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
P-AVP (pg/ml)
Placebo 0.87(0.5) 1.9(0.13) *** 1.5(0.12) *** 1.3(0.13) *** 1.2(0.9) *** NS
Ibuprofen 0.91(0.5) 1.9(0.15) *** 1.5(0.11) *** 1.4(0.10) *** 1.2(0.9) ***
U-OSM (mosm/kg H2O)
Placebo 130(25) 335(77) *** 588(113) *** 585(11) *** 566(110) *** NS
Ibuprofen 125(31) 331(107) *** 631(201) *** 625(119) *** 612(130) ***
S-OSM (mosm/kg H2O)
Placebo 283(2.7) 291(4.1) *** 290(3.2) *** 289(3.6) *** 287(3.7) *** NS
Ibuprofen 283(3.0) 293(3.7) *** 291(2.6) *** 289(3.2) *** 287(3.5) ***
U-PGE2 (pg/min)
Placebo 281(123) 212(105) 256(118) 293(133) 298(173) <0.001
Ibuprofen 507(341) 385(180) 415(138) 406(160) 507(411)
P-Value 0.02 0.001 0.0004 0.005 0.02
CH2O (ml/min)
Placebo 4.05(1.2) -0.38(0.5) *** -1.60(0.6) *** -2.00(0.7) *** -2.00(0.7) *** NS
Ibuprofen 3.70(1.4) -0.20(1.0) *** -1.62(0.8) *** -1.92(0.7) *** -2.00(0.7) ***
Urine (ml/min) Placebo 7.02(1.57) 3.0(0.19)*** 1.8(0.20)*** 2.16(0.20)*** 2.3(0.20)*** <0.0001
Ibuprofen 6.31(1.71) 2.8 (0.23)*** 1.6(0.12)*** 1.7(0.11)*** 1.9(0.13)***
P-Value NS NS NS 0.016 NS
U-CAMP (pmol/min)
Placebo 3819(1034) 3974(1251) 4285(1387) 4114(1353) 4219(1125) NS
Ibuprofen 4016(1180) 3738(759) 4447(1243) 4196(1248) 4377(1136)
GFR (ml/min)
Placebo 98(12) 94(16) 94(21) 103(21) 102(17) NS
Ibuprofen 98(13) 93(18) 98(15) 101(16) 103(12)
Baseline values before hypertonic saline infusion, 30, 60, 90 and 120 min after hypertonic saline infusion in 17 healthy humans administered with ibuprofen or
placebo.
Values are means and (SD). P indicates significant difference between ibuprofen treatment and placebo using a General Linear Model With Repeated Measures.
A paired t-test was used for comparison of means, when differences were found between the two treatments. *indicated a statistical significant changed from
baseline values* P < 0.05 ** P < 0.01, *** P < 0.001.(longitudinal comparison).
Lauridsen et al. BMC Nephrology 2010, 11:28
http://www.biomedcentral.com/1471-2369/11/28
Page 6 of 12a tt h es a m et i m et h e r ew a sad e c r e a s ei np - a l b u m i n
f r o m4 1g / la tb a s e l i n et o3 7g / l( p<0 . 0 0 1 )a tt h ee n d
of the study. None of the subjects had edema after infu-
sion of 3% sodium chloride.
Discussion
The present study of healthy subjects showed that ibu-
profen decreased FENa and increased u-ENaCb both dur-
ing a 24 hours fasting period, during the first two hours
after 24 hours fasting, and during the following period
with hypertonic saline infusion. The increased tubular
sodium absorption during ibuprofen treatment might be
attributed to increased sodium transport from the tubu-
lar lumen via the epithelial sodium channels. Our
hypothesis was not falsified regarding this point. How-
ever, ibuprofen decreased u-AQP2 and u-PGE2, and did
not change p-AVP, u-c-AMP, urinary output, and free
water clearance during any of the study periods. Thus,
our results demonstrated that u-AQP2 was reduced,
although an increased AQP2 trafficking might be
expected, when the antagonizing effect of prostaglandins
on the vasopressin mediated effect on the principal cells
was reduced/eliminated during ibuprofen treatment.
Consequently, our hypothesis that reduction of prosta-
glandin synthesis would increase u-AQP2 was falsified.
I nt h ep r e s e n ts t u d yw eh a v eu s e dan e wa n do r i g i n a l
method to evaluate sodium reabsorption in the principal
cells in the distal tubules using a radioimmunoassay of
the b-fraction of the protein in the epithelial sodium
channel. The amount of ENaCb in urine is supposed to
reflect the activity of sodium transport via the epithelial
sodium channels just as u-AQP2 reflects the functional
status of the AQP2 water channels (31). Our analyses
showed that the assay has a satisfactory reliability. In
addition, we demonstrated a significant correlation
between changes in urinary sodium excretion and
changes in u-ENaCb. Thus, our results are in accordance
with u-ENaCb being a biomarker of the transport of
sodium via ENaC during acute studies, presumably
reflecting up- and down regulation b-ENaC expression
and sodium transport via ENaC. It is well known that
ibuprofen reduces renal sodium excretion. Our study
adds new information, since our data might suggest that
prostaglandin inhibition possibly reduce renal sodium
excretion via an increased transport through ENaC.
In our study, ibuprofen significantly reduced FENa
during all parts of study to a level around 35% lower
than placebo. The response in FENa during hypertonic
saline infusion was the same during treatment with ibu-
profen and placebo, and the difference, i.e. the lower
level of FENa during ibuprofen treatment, persisted dur-
ing the infusion. Several animal studies have shown that
PGE2 has a direct inhibitory effect on sodium chloride
transport in the collecting ducts [2,5,13,14]. In rats, this
is regulated by the EP2 receptor[15]. We found that u-
ENaCb was significantly increased during ibuprofen
treatment. Thus, the decrease in FENa might, at least
partly, be explained by an increased transport of sodium
from the tubular lumen via ENaC. However, we cannot
exclude that the antinatriuretic effect of ibuprofen was
also attributed to some extent by an upregulation of the
Na-K-2Cl cotransporter in the ascending limb of Henle’s
loop [16]. U-ENaCb was increased by ibuprofen without
an increase in either p-AVP or u-c-AMP, which indi-
cates that AVP does not seem to play a direct regulatory
role in the increased u-ENaCb. However, the marked
r e d u c t i o ni nu - P G E 2 makes it likely that the reduced
prostaglandin level results in the increase sodium trans-
port via ENaC, and this explanation is supported by evi-
dence from animal studies [7,17-19].
Figure 1 Effect hypertonic saline infusion on ENaCb/crea in a
randomized placebo-controlled, cross-over study of 17 healthy
subjects.
Figure 2 Effect hypertonic saline infusion on fractional sodium
excretion (FENa) in a randomized placebo-controlled, cross-
over study of 17 healthy subjects.
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variables qualitatively during hypertonic saline infusion,
but renal sodium excretion was reduced as hypothe-
sized. After hypertonic saline infusion u-ENaC was
reduced significantly at 60 minutes, and at the same
time p-ANP tended to increase. An increase in ANP
might be responsible for reduction in u-ENaCb during
this condition, and could be seen as a homeostatic
mechanism to prevent sodium and fluid expansion [6].
Aldosterone is an important regulator of the transport
activity via ENaC. Aldosterone stimulates the MR recep-
tor. The result is an increased transcription of genes,
which code for proteins involved in sodium transport,
i. e. ENaC and Na-K-ATPase [3,20]. In-vitro and in-vivo
studies have shown that aldosterone increases the synth-
esis of the a-fraction of ENaC in the distal tubuli [21].
In our study, we found that u-ENaCb was reduced in
the ibuprofen group during and after hypertonic saline
infusion. We did not measure a reduction in p-aldoster-
one. This might be due to the fact that our study was
too short to allow the regulatory effect of aldosterone.
A time delay in aldosterone secretion has previously
been demonstrated in another study, in which an acute
infusion of hypertonic saline infusion decreased PRA,
but plasma aldosterone was unchanged [22]. We think
the short observation time after the hypertonic saline
infusion might explain the fact that p-aldosterone was
unchanged in the present study.
During placebo treatment, hypertonic saline resulted
in a significant increase in u-ENaCb. This increase was
associated with an increased FENa. The explanation of
this phenomenon is not clear for the time being. A con-
siderably decrease in the renal sodium absorption more
proximally in the nephron might be compensated for by
an increase in absorption in the distal part of the
nephron, but additional studies are required to deter-
mine the precise use of u-ENaCb as biomarker for
ENaC activity during these conditions. However, a rise
in the intracellular sodium concentration was suggested
to be a trigger for the feedback inhibition of sodium
absorption via ENaC in rats when expressed in xenopus
laevis oocytes [23]. Thus, the reduction in u-ENaCb dur-
ing sodium loading could alternatively be attributed to
this inhibitory feedback mechanism of increased intra-
cellular sodium on sodium transport via ENaC.
In a previous study, we showed that fasting decreased
u-AQP2 and reduced the stimulating effect of vasopres-
sin on u-AQP2 [24]. Fasting increased prostaglandin
synthesis, and the refractoriness to vasopressin during
fasting was proposed to be due to an antagonizing effect
of prostaglandins on AQP2 trafficking. Thus, it would
be reasonable to hypothesize that an increase in
u-AQP2 could be expected by ibuprofen treatment. On
the contrary, ibuprofen reduced u-PGE2 markedly in the
present study during all conditions i.e. in 24 hours
urine, in the period shortly after 24 hours of fasting, and
Table 4 Effect of Ibuprofen on plasma atrial natriuretic peptide (p-ANP), plasma brain natriuretic peptide (p-BNP),
plasma angiotensin II (p-AngII) and p-aldosterone (p-Aldo) at morning after 24 hours of fasting (morning), before
hypertonic saline infusion (baseline), 60 min. after hypertonic saline infusion (60 min. post) and 120 min. after
hypertonic saline infusion (120 min. post) compared with placebo in a randomized clinical trial with17 healthy
subjects
Morning Baseline 60 min. post. 120 min. post. P
p-ANP (pmol/l)
Placebo 5.95(3.37) 5.75(2.68) 9.84 (3.89) 8.39(4.03) NS
Ibuprofen 6.80(3.22) 7.44(3.46) 11.85(5.54) 9.13 (3.78)
p-BNP (pmol/l)
Placebo 1.59(1.10) 1.65(0.99) 2.66 (2.26) 2.17 (1.55) 0.015
Ibuprofen 2.57(2.08) 2.65(2.03) 3.44 (3.27) 3.09 (2.38)
p-value 0.025 0.004 NS 0.015
p-Renin (mU/l)
Placebo 10.1(5.3) 12.2(7.8) 9.5(14.7) 5.5 (2.1) NS
Ibuprofen 10.7(12.3) 13.6(22.1) 12.5 (21.3) 4.9 (2.5)
p-AngII(pmol/l
Placebo 8.2 (3.0) 10.5 (5.9) 6.5(4.4) 6.2 (3.5) NS
Ibuprofen 7.1 (3.4) 7.6 (4.6) 5.9 (4.0) 5.2 (2.7)
p-Aldo (pmol/l)
Placebo 310.8 (211.6) 230.4 (145.5) 164.7 (63.0) 162.4 (57.1) NS
Ibuprofen 293.9 (137.6) 190.9 (55.6) 156.6 (27.3) 161.6 (36.6)
Values are means and (SD). P indicates significant difference between ibuprofen treatment and placebo using a General Linear Model With Repeated Measures. A
paired t-test was used for comparison of means, when differences were found between the two treatments.
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ever, ibuprofen also reduced u-AQP2 during all parts of
the study, and thereby falsified our hypothesis that
reduction of prostaglandin synthesis would increase u-
AQP2.
A previous study in humans showed that prostacyclin
infusion increased u-AQP2 excretion, and this seems to
be in agreement with our results [25]. Apparently, a dis-
crepancy exists between animal studies on the one hand
and studies in man on the other. In animals, prostaglan-
din decreased APQ2 trafficking [2,26], and inhibition of
prostaglandin synthesis by infusion of indomethacin
increased urinary excretion of AQP2 [4]. In healthy man
prostaglandin and prostaglandin-inhibitors had the
opposite effects, as demonstrated in the present study
and by others [25]
We found that ibuprofen significantly reduced u-PGE2
due to a reduced renal prostaglandin synthesis. This is
in accordance with other studies in healthy man [27,28].
Prostaglandin E2 increased urinary output and sodium
excretion by inhibition of AVP stimulated water absorp-
tion, inhibition of sodium absorption and stimulation of
basal water absorption [8]. Different subtypes of prosta-
glandin receptors mediate this effect from the basolat-
eral part of the tubular cells [29]. Receptor stimulation
by PGE2 reduced sodium reabsorption in the thick
ascending limb of Henle and in the cortical collecting
duct, and reduced AVP-induced water absorption in
cortical collecting duct [9,30,31]. Both p-AVP and
u-c-AMP were unchanged by ibuprofen, but simulta-
neously we measured a clear reduction in u-AQP2.
Thus, the vasopressin-c-AMP axis was not involved in
the reduction in u-AQP2. It is generally accepted that
prostaglandin E2 antagonizes the effect of vasopressin
on AQP2 trafficking via the EP3 receptor. Activation of
this receptor inhibits adenylyl-cyclase, reduces the level
of c-AMP, causing increased urinary output. However,
the close relationship between c-AMP production and
increased AQP2 trafficking was challenged in a recent
experimental study [32]. Activation of the EP3 receptor
inhibited AQP2 trafficking in inner medullary cells from
rats, despite high levels of c-AMP, probably due to an
cAMP- and Ca2+-independent Rho activation. Rho pro-
motes the formation F-actin which hinders AQP2
coated vesicles reaching the apical membrane [32]. Our
study in healthy man is in agreement with these find-
ings, in the sense that we found a reduction in u-AQP2
excretion without changes in urinary excretion of c-
AMP. This suggests that adenylyl cyclase activity did
not contribute to our results regarding u-AQP2 excre-
tion. The changes in p-AVP during hypertonic saline
infusion was as expected, and the changes were not sig-
nificantly different during ibuprofen treatment com-
pared with placebo.
As expected, we measured a marked reduction in
urinary sodium excretion during ibuprofen treatment as
reflected in the decrease in FENa, but no significant
changes in urinary output and free water clearance.
However, some tubular reabsorption of water must take
place simultaneously with sodium reabsorption due to
the effect of ibuprofen on basal renal water transport.
Most likely, this fact explains our findings, i.e. the lack
of increase in urinary output and free water clearance
despite decreased u-AQP2 during ibuprofen treatment.
Both p-AVP and u-c-AMP were unchanged by ibupro-
fen, but simultaneously we measured a clear reduction
in u-AQP2. Thus, the vasopressin-c-AMP axis was not
involved in the reduction in u-AQP2. The changes in
p-AVP during hypertonic saline infusion was as
expected, and the changes were not significantly differ-
ent during ibuprofen treatment compared with placebo.
However, other regulatory factors than vasopressin
and prostaglandins may influences the expression of
AQP2 and u-AQP2 such as the renin-angiotensin-aldos-
terone system, the natriuretic peptide system, and the
sympathetic nervous system [1,6,33-38]. We measured
higher levels of p-BNP and a clear tendency to an
increase in p-ANP simultaneous with a tendency to a
lower level of p-Ang II and p-Aldo during ibuprofen
treatment. Most likely, these changes in hormones with
both vasoactive- and sodium- and water regulating
properties are secondary to the sodium retention
induced by ibuprofen. This is supported by the fact that
p-albumin fell significantly, and that body weight tended
to increase, presumably due to an expansion of the
extracellular fluid volume. Animal studies support this
explanation. Angiotensin II stimulated/enhanced AQP2
expression [36,38], and angiotensin II receptor blockade
reduced AQP2 expression [1]. Aldosterone agonism and
antagonism increased and decreased AQP2 expression,
respectively [34]. We suggest that the tendency to
reduced levels of the components in the renin-angioten-
sin-aldosterone system contributes to the reduced level
of u-AQP2 during ibuprofen treatment in fasting healthy
humans.
The role of ANP in the regulation of intracellular
distribution of AQP2 was addressed in rats [6]. ANP-
infusion had no immediate effect on the intracellular
localization of AQP2, but after 90 minutes of ANP-
infusion an increased apical targeting of AQP2 was
noted. This was regarded as either a direct or compen-
satory effect to volume depletion to avoid dehydration.
A human study with head out water immersion demon-
strated increased AQP2 expression accompanied by an
increase in p-ANP [33]. These findings do not prove
any causal relationship, as several other homeostatic
systems as the sympathetic nervous system and the
renin-angiotensin-aldosterone system are also influenced
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peptide system on AQP2 trafficking and urinary excre-
tion is not fully elucidated. Accordingly, we cannot rule
out that the increased levels of the natriuretic peptides
after ibuprofen treatment had modulated u-AQP2 in
our study.
Inhibition of the renal prostaglandin synthesis might
be dangerous in patients with heart failure, lever disease
and renal insufficiency. It can result in sodium and
water retention and hypertension. We did not measure
any changes in blood pressure and the increase in body
weight was marginal. Most like, this can be attributed to
the fact that we studied healthy subjects.
Conclusions
In conclusion, ibuprofen decreased urinary sodium
excretion considerably in healthy man during fasting, a
state with an increased prostaglandin synthesis. During
the reduced prostaglandin synthesis u-ENaCb was mark-
edly increased. Our results suggest that prostaglandins
have an important direct regulatory function on ENaC
trafficking. During hypertonic saline infusion, angioten-
sin II and aldosterone tended to decrease in plasma and
the natriuretic peptides increased, which presumably
can be seen as compensatory phenomena to prevent
extracellular fluid expansion. Surprisingly, ibuprofen also
decreased urinary u-AQP2 both during 24 hours of fast-
ing and during hypertonic saline infusion. This effect
was not mediated via the vasopressin-c-AMP-axis, but
may be mediated by the changes in the natriuretic pep-
tide system and/or the angiotensin-aldosterone system.
Appendix
Description of the u-ENaCb analysis, ENaCb was mea-
s u r e db yan e w l yd e v e l o p e dR I A .U r i n es a m p l e sw e r e
kept frozen at -20°C until assayed. ENaCb was synthe-
sized and and purchased by Lofstrand Labs Limited -
Gaithersburg, Maryland, USA.
The b-ENaC antibody was raised against a synthethic
peptide in rabbits and affinity purified as previously
described [39] Iodination of ENaCb was performed by
the chloramine T method using 40 μgo fE N a C b and 37
MBq
125I. The reaction was stopped by addition of 20%
human serum albumin.
125I-labeled ENaCb was sepa-
rated from the iodination mixture by the use of a Sepha-
dex G-25 Fine column. The assay buffer was 40 mM
sodium phosphate (pH = 7.4), 0.2% human albumin,
0.1% Triton X-100, and 0.4% EDTA. A 1.5% solution of
gamma globulins from pig (Sigma) and 25% polyethy-
lene glycol 6000 (Merck) also containing 0.625% Tween
20 (Merck) was prepared using the 0.4 M phosphate
buffer. Urine samples were kept frozen at - 20°C. After
thawing out urine samples were centrifuged for 5 min at
1.6 × 100 g (3,000 rpm). The supernatant was extracted
using Sep-pak C18. The eluation fluid was 4 ml of a
mixture comprising 90% methanol, 0.5% acetic acid and
9.5% demineralized water. The eluates were freeze-dried
and kept at - 20°C until assayed. The mixture of 300 μl
of standard or freeze-dried urine eluates redissolved in
300 μl assay buffer and 50 μl of antibody was incubated
for 24 h at 4°C. Thereafter, 50 μl of the tracer were
added, and the mixture was incubated for a further 24 h
at 4°C. Gamma globulin from pigs (100 μl) and 2 ml
polyethylene glycol 6000 were added. The mixture was
centrifuged at 3,500 rpm for 20 min at 4°C. The super-
natant (free fraction) was poured off, and the precipitate
(bound fraction) was counted in a gamma counter. The
unknown content in urine extracts was read from a
standard curve. For 13 consecutive standard curves, the
zero standard was 70 ± 1.6%, and for increasing
amounts of ENaCb standard the binding inhibition was:
69 ± 1.4% (15.6 pg/tube), 66 ± 1.5% (31.25 pg/tube), 62
± 1.6% (62.5 pg/tube), 54 ± 1.5% (125 pg/tube), 40 ±
1.4% (250 pg/tube), 26 ± 1.2% (500 pg/tube), 14 ± 0.6%
(1000 pg/tube), 8.2 ± 0.4% (2000 pg/tube), and 5.1 ±
0.3% (4000 pg/tube). The ID 50, i.e. the concentration
of standard needed for 50% binding inhibition was 322
± 12 pg/tube (n = 13). The nonspecific binding deter-
mined by performing the RIA without antibody was 1.3
±0 . 3 %( n=1 3 ) .T h ei n t e r - a s s a yv a r i a t i o nw a sd e t e r -
mined by quality controls from the same urine pool
spiked with ENaCb standard. In consecutive assays the
coefficient of variation was: at a mean level of 78 pg/
tube 12% (12 assays), at a mean level of 155 pg/tube
10% (12 assays), and at a mean level of 394 pg/tube 17%
(10 assays). The intra-assay variation was determined on
samples from the same urine pool in several assays at
different concentration levels. At a mean level of 180
pg/tube (n = 10) and 406 pg/tube (n = 10), the coeffi-
cients of variation were 6.4% and 9.0%, respectively. In
addition, coefficients of variation were calculated on the
basis of duplicate determinations in different assays to
9.1% (n = 22) in the range 58-101 pg/tube, 8.6% (n =
26) in the range 143-203 pg/tube, 8.7% (n = 20) in the
range 205-421 pg/tube, and 10.0% (n = 68) in the whole
range 58-421 pg/tube. The sensitivity calculated as the
smallest detectable difference at the 95% confidence
limit was 10 pg/tube in the range 58-101 pg/tube (n =
22), 20 pg/tube in the range 143-203 pg/tube (n = 26),
48 pg/tube in the range 205-421 pg/tube (n = 20), and
28 pg/tube in the whole range 58-421 pg/tube (n = 68).
The lower detectable limit of the assay was 34 pg/tube.
It was calculated using the average zero binding for 13
consecutive assays minus 2 SD. The volume of urine
used for extraction from the same pool was varied (18
different volumes in the range 250-6000 μl), and the
mean concentration measured was 89 ± 6 pg/ml. There
was a highly significant correlation between the
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(r = 0.99, n = 18). Recovery of the labeled tracer during
the extraction-freezing drying procedure was 94 ± 3%
(n = 13), 95 ± 3% (n = 13), 95 ± 2% (n = 10), and 95 ±
2% (n = 7) in four different pools used in several extrac-
tion procedures. When ENaCb in the range 62.5 to
250 pg was added to urine, a highly significant correla-
tion was found between the measured and the expected
values (r = 0.981, n = 12, P < 0.001). We measured
u-ENaCb in 9 patients with arterial hypertension treated
with amiloride. During the study day, patients collected
a urine sample at 08.00 and 11.00. They took no medi-
cation in the morning before the first urine sample.
Immediately after the first urine sampling, the patients
took their usually dosis of amiloride 5 or 10 mg. For the
whole group a significant correlation was found between
the changes in u-Na/Crea and changes in u-ENaCb/crea
(r = -0.720, n = 9, P = 0.029).
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